Indiana § 12-23-18-7.5 - Office based opioid treatment providers; treatment protocol; clinical practice guidelines

§ 12-23-18-7.5. Office based opioid treatment providers; treatment protocol; clinical practice guidelines

Sec. 7.5. (a) This section applies to an office based opioid treatment provider who:

(1) has obtained a waiver from the federal Substance Abuse and Mental Health Services Administration (SAMHSA) and meets the qualifying standards required to treat opioid addicted patients in an office based setting; and

(2) has a valid federal Drug Enforcement Administration registration number and identification number that specifically authorizes treatment in an office based setting.

(b) The office of the secretary and the division shall develop a treatment protocol containing best practice guidelines for the treatment of opiate dependent patients. The treatment protocol must require the minimal clinically necessary medication dose, including, when appropriate, the goal of opioid abstinence, and including the following:

(1) Appropriate clinical use of any drug approved by the federal Food and Drug Administration for the treatment of opioid addiction, including the following:

(A) Opioid maintenance.

(B) Opioid detoxification.

(C) Overdose reversal.

(D) Relapse prevention.

(E) Long acting, nonaddictive medication assisted treatment medications.

(2) A requirement for initial and periodic behavioral health assessments for each patient.

(3) Appropriate use of providing overdose reversal, relapse prevention, counseling, and ancillary services.

(4) Transitioning off agonist and partial agonist therapies, when appropriate, with the goal of opioid abstinence.

(5) Training and experience requirements for prescribers of drugs described in subdivision (1) in the treatment and management of opiate dependent patients.

(6) A requirement that prescribers obtain informed consent from a patient concerning all available opioid treatment options, including each option's potential benefits and risks, before prescribing a drug described in subdivision (1).

(c) Before December 31, 2016, the office of the secretary shall recommend the clinical practice guidelines required under subsection (b) to:

(1) the Indiana professional licensing agency established under IC 25-1-5;

(2) the office of Medicaid policy and planning established under IC 12-8-6.5; and

(3) a managed care organization that has contracted with the office of Medicaid policy and planning.

As added by P.L.8-2016, SEC.5.